eplontersen sodium - Profile
What are the generic drug sources for eplontersen sodium and what is the scope of patent protection?
Eplontersen sodium
is the generic ingredient in two branded drugs marketed by Astrazeneca Ab and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Summary for eplontersen sodium
| International Patents: | 263 |
| US Patents: | 4 |
| Tradenames: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for eplontersen sodium
Generic Entry Date for eplontersen sodium*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for eplontersen sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | WAINUA | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-002 | Apr 15, 2026 | RX | Yes | Yes | 10,683,499 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Astrazeneca Ab | WAINUA | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-002 | Apr 15, 2026 | RX | Yes | Yes | 9,181,549 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Astrazeneca Ab | WAINUA | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-002 | Apr 15, 2026 | RX | Yes | Yes | 9,127,276 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | 10,683,499 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | 9,127,276 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | 9,181,549 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for eplontersen sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | 8,101,743 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for eplontersen sodium
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2014259750 | ⤷ Start Trial | |
| Australia | 2014259755 | ⤷ Start Trial | |
| Australia | 2014259756 | ⤷ Start Trial | |
| Australia | 2014259757 | ⤷ Start Trial | |
| Australia | 2014259759 | ⤷ Start Trial | |
| Australia | 2017200365 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for eplontersen sodium
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2991656 | 26C1005 | France | ⤷ Start Trial | PRODUCT NAME: OLEZARSEN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/25/1969 20250918 |
| 3524680 | 28/2025 | Austria | ⤷ Start Trial | PRODUCT NAME: EPLONTERSEN, OPTIONAL IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/24/1875 (MITTEILUNG) 20250307 |
| 3524680 | 301341 | Netherlands | ⤷ Start Trial | PRODUCT NAME: EPLONTERSEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/24/1875 20250307 |
| 2991656 | 122026000005 | Germany | ⤷ Start Trial | PRODUCT NAME: OLEZARSEN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; AUTHORISATION NO/DATE: EU/1/25/1969 20250917 |
| 2991656 | 301361 | Netherlands | ⤷ Start Trial | PRODUCT NAME: OLEZARSEN OF FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/25/1969 20250918 |
| 3524680 | C20250028 | Finland | ⤷ Start Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Investment Scenario and Fundamentals Analysis for Eplontersen Sodium
More… ↓
